Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden

References

• Tan SL, Pause A, Shi Y, Sonenberg N. Hepatitis C therapeutics: current status and emerging strategies. Nat Rev Drug Discov. 2002; 1: 867–81.
   Google Scholar
• Thibault V, Bara JL, Nefau T, Duplessy-Garson C. Hepatitis C transmission in injection drug users: could swabs be the main culprit?. J Infect Dis. 2011; 204: 1839–42.
   Google Scholar
• Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, etal. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002; 155: 645–53.
   Google Scholar
• Oliveira MdLA, Bastos FI, Telles PR, Hacker MdA, Oliveira SANd, Miguel JC, etal. Epidemiological and genetic analyses of hepatitis C virus transmission among young/short- and long-term injecting drug users from Rio de Janeiro, Brazil. J Clin Virol. 2009; 44: 200–6.
   Google Scholar
• Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, etal. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction. 2009; 104: 1881–90.
   Google Scholar
• Nakano T, Lau GMG, Lau GML, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2012; 32: 339–45.
   Google Scholar
• Sentandreu V, Jiménez-Hernández N, Torres-Puente M, Bracho MA, Valero A, Gosalbes MJ, etal. Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS One. 2008; 3: e3239.
   Google Scholar
• Linhart C, Shamir R. The degenerate primer design problem. Bioinformatics. 2002; 18: S172–S81.
   Google Scholar
• Jungkind D. Automation of laboratory testing for infectious diseases using the polymerase chain reaction—our past, our present, our future. J Clin Virol. 2001; 20: 1–6.
   Google Scholar
• Le Guillou-Guillemette H, Lunel-Fabiani F. Detection and quantification of serum or plasma HCV RNA: mini review of commercially available assays. 2009; 510: 3–14. Methods Mol Biol.
   Google Scholar
• Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002; 36: S21–S9.
   Google Scholar
• Palanisamy N, Danielsson A, Kokkula C, Yin H, Bondeson K, Wesslén L, etal. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a. Antiviral Res. 2013; 99: 12–17.
   Google Scholar
• Yin H, Bondeson K, Lennerstrand J. Prevalence of natural resistance by HCV to protease inhibitors. Antivir Ther. 2010; 15: A91.
   Google Scholar
• Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011; 28: 2731–9.
   Google Scholar
• Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics. 2005; 21: 379–84.
   Google Scholar
• Lappalainen M, Chen RW, Maunula L, von Bonsdorff CH, Plyusnin A, Vaheri A. Molecular epidemiology of viral pathogens and tracing of transmission routes: hepatitis-, calici- and hantaviruses. J Clin Virol. 2001; 21: 177–85.
   Google Scholar
• Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, etal. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ. 2001; 323: 1209–13.
   Google Scholar
• Alvarado-Esquivel C, Sablon E, Martínez-García S, Estrada-Martínez S. Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect. 2005; 133: 679–85.
   Google Scholar
• Månsson AS, Moestrup T, Nordenfelt E, Widell A. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000; 32: 253–8.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45: 1056–75.
   Google Scholar
• Sylvan SPE, Hedlund J, Ohlén G, Lundell E, Bondeson K, The Uppsala County Working Group Against Drug Dependency . Seroepidemiology and risk factors of blood-borne virus infections among drug users in Uppsala County, Sweden. The Open Infect Dis J. 2008; 2: 27–31.
   Google Scholar
• Rolls DA, Daraganova G, Sacks-Davis R, Hellard M, Jenkinson R, McBryde E, etal. Modelling hepatitis C transmission over a social network of injecting drug users. J Theor Biol. 2012; 297: 73–87.
   Google Scholar
• Skar H, Sylvan S, Hansson HB, Gustavsson O, Boman H, Albert J, etal. Multiple HIV-1 introductions into the Swedish intravenous drug user population. Infect Genet Evol. 2008; 8: 545–52.
   Google Scholar
• Roy É, Haley N, Leclerc P, Cédras L, Boivin JF. Drug injection among street youth: the first time. Addiction. 2002; 97: 1003–9.
   Google Scholar
• Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, etal. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006; 20: 701–10.
   Google Scholar
• Escobar-Gutiérrez A, Vazquez-Pichardo M, Cruz-Rivera M, Rivera-Osorio P, Carpio-Pedroza JC, Ruíz-Pacheco JA, etal. Identification of hepatitis C virus transmission using a next generation sequencing approach. J Clin Microbiol. 2012; 50: 1461–3.
   Web of Science ®Google Scholar